Celyad Oncology S.A.
CYAD.BR · BRU
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €186 | €102 | €0 | €0 |
| % Growth | 82.4% | – | – | – |
| Cost of Goods Sold | -€733 | €69 | €1,440 | €1,520 |
| Gross Profit | €919 | €33 | -€1,440 | -€1,520 |
| % Margin | 494.1% | 32.4% | – | – |
| R&D Expenses | €2,886 | €4,668 | €17,697 | €19,496 |
| G&A Expenses | €3,088 | €5,707 | €10,337 | €9,665 |
| SG&A Expenses | €4,292 | €6,250 | €10,337 | €9,665 |
| Sales & Mktg Exp. | €78 | €215 | €0 | €0 |
| Other Operating Expenses | €0 | -€2,428 | €0 | €328 |
| Operating Expenses | €7,178 | €8,490 | €28,034 | €29,489 |
| Operating Income | -€6,259 | -€10,597 | -€29,474 | -€26,391 |
| % Margin | -3,365.1% | -10,389.2% | – | – |
| Other Income/Exp. Net | €299 | €1,958 | -€11,858 | -€111 |
| Pre-Tax Income | -€5,960 | -€8,639 | -€41,332 | -€26,502 |
| Tax Expense | -€136 | -€191 | €65 | €10 |
| Net Income | -€5,824 | -€8,448 | -€40,935 | -€26,512 |
| % Margin | -3,131.2% | -8,282.4% | – | – |
| EPS | -0.14 | -0.33 | -1.81 | -1.7 |
| % Growth | 57.6% | 81.8% | -6.5% | – |
| EPS Diluted | -0.14 | -0.33 | -1.81 | -1.7 |
| Weighted Avg Shares Out | 41,429 | 25,722 | 22,594 | 15,604 |
| Weighted Avg Shares Out Dil | 41,429 | 25,722 | 22,594 | 15,604 |
| Supplemental Information | – | – | – | – |
| Interest Income | €153 | €30 | €12 | €27 |
| Interest Expense | €119 | €84 | €197 | €255 |
| Depreciation & Amortization | €450 | €794 | €1,440 | €1,520 |
| EBITDA | -€5,391 | -€7,763 | -€39,695 | -€25,414 |
| % Margin | -2,898.4% | -7,610.8% | – | – |